文献速递白血病

一种靶向急性髓系白血病CD33的高效四价T细胞衔接双特异性抗体

A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2018-01-01

该研究报道一种四价(2+2)人源化IgG(L)-scFv双特异性抗体,可衔接多克隆T细胞杀伤CD33+急性髓系白血病靶细胞。体外实验显示其抗原特异性T细胞依赖性细胞毒性(TDCC)的半数有效浓度(EC50)在飞摩尔范围,并在体内可治疗已建立的人源AML静脉异种移植瘤。该双特异性抗体不识别也不杀伤脐带血CD38-CD34+造血干细胞,作者认为其是临床开发的潜在候选。

要点

  • 四价(2+2)人源化IgG(L)-scFv双特异性抗体可衔接多克隆T细胞杀伤CD33+ AML靶细胞。
  • 体外TDCC的EC50在飞摩尔范围,并转化为体内治疗已建立的人源AML静脉异种移植瘤。
  • 该双特异性抗体不识别也不杀伤脐带血CD38-CD34+造血干细胞。

核心结论

  • 作者认为,所报道的新型抗CD33 IgG(L)-scFv双特异性抗体构建体是临床开发的潜在候选。

研究设计与样本

  • 研究报道一种四价(2+2)人源化免疫球蛋白G轻链单链片段可变区[IgG(L)-scFv]格式的双特异性抗体,用于衔接多克隆T细胞杀伤CD33+ AML靶细胞。

主要发现

  • 体外,该双特异性抗体表现出强抗原特异性T细胞依赖性细胞介导的细胞毒性(TDCC),EC50在飞摩尔范围,并转化为体内治疗已建立的人源AML静脉异种移植瘤。
  • 该双特异性抗体可将腹腔注射的T细胞重定向,以消融已建立且快速生长的髓外皮下AML异种移植瘤。
  • 双特异性抗体结合后CD33的内化与二价(1+1)异二聚体相同,两者均 substantially 低于抗CD33 IgG。
  • 与异二聚体相比,四价IgG-scFv双特异性抗体在体外和体内对AML细胞的TDCC效率高>10倍。
  • 该双特异性抗体不与脐带血CD38-CD34+造血干细胞反应,也不杀伤这些细胞。

临床怎么用

  • 原文未据此给出推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML), the most common acute leukemia in adults and the second most common cancer in children, is still a lethal disease in the majority of patients, but immunologic approaches have improved outcome. Bispecific antibodies (BsAbs) are novel immunotherapeutics that can redirect immune cells against AML. We now report a tetravalent (2+2) humanized BsAb in the immunoglobulin G light chain single chain fragment variable [IgG(L)-scFv] format to engage polyclonal T cells to kill CD33+ AML targets. In vitro, this BsAb demonstrated strong antigen-specific T-cell-dependent cell-mediated cytotoxicity (TDCC) with an 50% effective concentration (EC50) in the femtomolar range that translated into treatment of established human AML IV xenografts in vivo. Importantly, it could redirect intraperitoneally injected T cells to ablate established and rapidly growing extramedullary subcutaneous AML xenografts in vivo. Furthermore, internalization of CD33 upon BsAb binding was identical to that of a bivalent (1+1) heterodimer, both being substantially less than anti-CD33 IgG. In contrast to the heterodimer, the tetravalent IgG-scFv BsAb was >10-fold more efficient in TDCC of AML cells in vitro and in vivo. This BsAb did not react with and did not kill CD38-CD34+ hematopoietic stem cells from cord blood. We conclude that the novel anti-CD33 IgG(L)-scFv BsAb construct reported here is a potential candidate for clinical development.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hoseini SS, Guo H, Wu Z, et al. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Adv. 2018. PMID: 29858209. doi:10.1182/bloodadvances.2017014373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。